CF PharmTech, Inc., a Suzhou, China-based specialty pharmaceutical company that develops and manufactures inhalation products, raised $65M in Series D financing.
The round was led by Future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited (“SDIC Fund Management”), with other healthcare investment groups in China.
The company intends to use the funds to expedite the submission of its product pipeline to meet regulatory approvals in China and abroad and expand its CDMO service to international clients.
Founded by seasoned industry experts and entrepreneurs in the US pharmaceutical industry, CF PharmTech is focused on the development, manufacturing and commercialization of metered dose inhaler, inhalation powder, nasal spray and blow-fill-seal products for the global market.
Since its inception, the company has established research and manufacturing facilities to advance its product development.